Zobrazeno 1 - 10
of 127
pro vyhledávání: '"genotype 1a"'
Autor:
Faydra I. Lieveld, Niels Swaans, Astrid M. Newsum, Cynthia K.Y. Ho, Janke Schinkel, Richard Molenkamp, Jan T.M. van der Meer, Joop E. Arends, Andy I.M. Hoepelman, Anne M.J. Wensing, Peter D. Siersema, Karel J. van Erpecum, Greet J. Boland
Publikováno v:
Annals of Hepatology, Vol 15, Iss 5, Pp 696-704 (2016)
Background and aim. Resistance-associated variants (RAVs) on the NS3 region of the hepatitis C virus (HCV) may be relevant for antiviral therapy, but data in human immunodeficiency virus (HIV) coinfected patients are scarce. We assessed frequencies o
Externí odkaz:
https://doaj.org/article/ef7f7c7b6ddf4c0f9a907447d000c29e
Autor:
Nora A Fierro, Karina González-Aldaco, Rafael Torres-Valadez, Maria E Trujillo-Trujillo, Sonia Roman, Jorge L Trujillo-Ochoa, Arturo Panduro/
Publikováno v:
Memorias do Instituto Oswaldo Cruz, Vol 110, Iss 2, Pp 267-271 (2015)
The mechanisms related to the spontaneous clearance of hepatitis C virus (HCV) have been primarily studied in regions where the infection is endemic. Results of prior studies have been extrapolated to populations with low endemicity, such as Mexico.
Externí odkaz:
https://doaj.org/article/220d6a2fd12949c1981ddc45190123dd
Publikováno v:
ACS Medicinal Chemistry Letters
HCV NS5A inhibitors are the backbone of directly acting antiviral treatments against the hepatitis C virus (HCV). While these therapies are generally highly curative, they are less effective in some specific HCV patient populations. In the search for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0917aba5998f11af0fda77a0760cebd3
https://doi.org/10.1021/acsmedchemlett.1c00391
https://doi.org/10.1021/acsmedchemlett.1c00391
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Luciana Bonome Zeminian, Juliana Lara Padovani, Sílvia Maria Corvino, Giovanni Faria Silva, Maria Inês de Moura Campos Pardini, Rejane Maria Tommasini Grotto
Publikováno v:
Memorias do Instituto Oswaldo Cruz, Vol 108, Iss 1, Pp 13-17 (2013)
The goal of treatment of chronic hepatitis C is to achieve a sustained virological response, which is defined as exhibiting undetectable hepatitis C virus (HCV) RNA levels in serum following therapy for at least six months. However, the current treat
Externí odkaz:
https://doaj.org/article/02987132bc22495e9817b512af2a5903
Autor:
Hartwig Klinker, Karen Martin, Renate Heyne, Christine John, Markus Cornberg, Albrecht Stoehr, Holger Hinrichsen, Veronika Guenther, V Witte, Karl-Georg Simon, Stefan Zeuzem
Publikováno v:
European Journal of Gastroenterology & Hepatology
Background For treatment of genotype 1a (GT1a) infection with elbasvir/grazoprevir, the German guidelines recommend a differentiated approach depending on baseline viral load (BVL). For low BVL ≤800 000 IU/mL, treatment with 12 weeks elbasvir/grazo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63cc35bc9155afa0438445f82f27f71a
https://doi.org/10.1097/meg.0000000000001759
https://doi.org/10.1097/meg.0000000000001759
Publikováno v:
BioTechniques, Vol 52, Iss 4, Pp 273-275 (2012)
The use of subgenomic replicon systems has long been a valuable screening tool for the discovery of small molecule antivirals against Hepatitis C virus. While genotype 1a replicon systems have been widely used in stable systems, use in transient assa
Externí odkaz:
https://doaj.org/article/158a17fc7b8d4344add5cb0992448489
Autor:
Roger Trinh, Akshanth R. Polepally, Natarajan Ravendhran, Leslie Bank, Paul J. Pockros, Robert Reindollar, Fred Poordad, Marisol Martinez, Michael S. Epstein, David E. Bernstein, David R. Nelson, Shahriar Sedghi, Michael R. Lucey, Preethi Krishnan, Kristina Unnebrink
Publikováno v:
Journal of Viral Hepatitis
Patients infected with hepatitis C virus (HCV) treated with interferon‐free direct‐acting antivirals may still require ribavirin. However, ribavirin is associated with adverse events that can limit its use. This open‐label, multicentre, Phase 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f98a2630727fcd42cfacf6f7056bd160
https://doi.org/10.1111/jvh.13109
https://doi.org/10.1111/jvh.13109
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lieveld, Faydra I., Swaans, Niels, Newsum, Astrid M., Ho, Cynthia K. Y., Schinkel, Janke, Molenkamp, Richard, van der Meer, Jan T. M., Arends, Joop E., Hoepelman, Andy I. M., Wensing, Anne M. J., Siersema, Peter D., van Erpecum, Karel J., Boland, Greet J.
Publikováno v:
Annals of Hepatology, Vol 15, Iss 5, Pp 696-704 (2016)
Annals of hepatology, 15(5), 696-704. Mexican Association of Hepatology
Annals of hepatology, 15(5), 696-704. Mexican Association of Hepatology
Background and aim. Resistance-associated variants (RAVs) on the NS3 region of the hepatitis C virus (HCV) may be relevant for antiviral therapy, but data in human immunodeficiency virus (HIV) coinfected patients are scarce. We assessed frequencies o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::d6a63deee905baacd8e380117a2f2a97
http://www.sciencedirect.com/science/article/pii/S1665268119306313
http://www.sciencedirect.com/science/article/pii/S1665268119306313